Actavis seeks FDA ANDA authorization for generic Zubsolv.

Actavis seeks FDA ANDA authorization for generic Zubsolv, confirms patent challenge Actavis plc today confirmed that it offers filed an Abbreviated New Medication Application with the U.S. Food and Drug Administration seeking approval to advertise Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Related StoriesMylan sued regarding the ANDA submitting for generic version of ZytigaMylan announces U.S.At the final end of 2014, BioMed Central and other publishers alerted the international Committee on Publication Ethics to new forms of systematic attempts to manipulate journals’ peer-review processes. According to a statement published on COPE’s website in January 2015, these efforts to hijack the scholarly review program were apparently orchestrated by agencies that initial helped authors create or enhance their scientific articles and then marketed them favorable peer reviews.4 BioMed Central conducted a comprehensive investigation of all their recently published content articles and identified 43 which were published based on reviews from fabricated reviewers.